The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 227.50
Bid: 226.50
Ask: 228.00
Change: 2.00 (0.89%)
Spread: 1.50 (0.662%)
Open: 228.00
High: 228.50
Low: 224.50
Prev. Close: 225.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

Fri, 17th Nov 2023 07:58

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

UK retail sales declined last month despite expectations of a month-on-month increase, and declined faster than expected on an annual basis, official numbers on Friday showed.

"Cost of living pressures, reduced footfall and the great British weather all played their part. There are signs that cracks are starting to appear in the economy with consumers tightening their belts and switching to cheaper brands. Consumers are still spending more and getting less with retail sales volumes now at their lowest level since February 2021," said Wealth Club's Charlie Huggins.

Meanwhile, Swissquote Bank analyst Ipek Ozkardeskaya was upbeat ahead of the final day of trading this week, particularly when reflecting upon the week's news coming out of the US.

"This week could hardly be better in terms of economic, political, and geopolitical news. The US inflation slowed more than expected, the US politicians inked a short-term deal to avert a shutdown," said Ozkardeskaya.

"On top, the US retail sales fell last month, but fell less than expected, the initial jobless claims rose, and the US unemployment benefits reached the highest level in almost two years, factory production fell more than expected and homebuilder sentiment fell to the lowest level for the year."

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called up 0.4% at 7,441.17

----------

Hang Seng: down 2.1% at 17,452.71

Nikkei 225: closed up 0.5% at 33,585.20

S&P/ASX 200: closed down 0.1% at 7,049.40

----------

DJIA: closed down 45.74 points, or 0.1%, at 34,945.47

S&P 500: closed up 5.36 points, or 0.1%, at 4,508.24

Nasdaq Composite: closed up 9.84 points, or 0.1%, at 14,113.67

----------

EUR: down at USD1.0839 (USD1.0840)

GBP: down at USD1.2377 (USD1.2398)

USD: down at JPY150.50 (JPY151.34)

Gold: up at USD1,986.42 per ounce (USD1,966.26)

(Brent): down at USD77.41 a barrel (USD80.84)

(changes since previous London equities close)

----------

ECONOMICS

----------

Friday's key economic events still to come:

10:00 CET EU balance of payments

11:00 CET EU CPI

08:30 EST US housing starts

08:30 CST US Fed Chicago President Austan Goolsbee speaks

10:00 EST US advance quarterly services

US FRB Boston President Susan Collins speaks

US Federal Reserve Board Vice Chair Michael Barr speaks

UK BoE Deputy Governor David Ramsden speaks

----------

According to the Office for National Statistics, retail sales volumes declined 2.7% year-on-year in October, quickening from a 1.3% decline in September. The September figure was revised from a previous 1.0% decline. The October read also came in worse than feared, with market expectations of a 1.5% decline, according to FXStreet-cited consensus. Retail sales declined 0.3% in October from September, falling short of consensus. A monthly increase of 0.3% was forecast, according to FXStreet. In September, retail sales had fallen 1.1% from August, revised from a previous 0.9% decline. "Non-food stores sales volumes fell by 0.2% in October 2023, following a 2.1% fall in September 2023; retailers suggested that cost of living, reduced footfall and the wet weather in the second half of the month contributed to the fall," the ONS noted.

----------

US President Joe Biden has signed a temporary spending bill a day before a potential government shutdown. The move pushes a fight with congressional Republicans over the federal budget into the new year, and wartime aid for Ukraine and Israel remains stalled. The measure passed the US house and senate by wide bipartisan margins this week, ensuring the government remains open until after the holiday season. It also potentially giving legislators more time to sort out their considerable differences over government spending levels for the current fiscal year. Biden signed the bill in San Francisco, where he is hosting the summit of Asia-Pacific Economic Co-operation economies.

----------

BROKER RATING CHANGES

----------

Barclays raises NatWest to 'overweight' (equal weight) - price target 330 (315) pence

----------

Barclays raises Babcock International to 'overweight' (equal weight) - price target 529 (325) pence

----------

Jefferies cuts Great Portland Estates to 'underperform' (hold) - price target 352 (387) pence

----------

COMPANIES - FTSE 100

----------

AstraZeneca said its Truqap treatment for patients with advanced hormone receptor positive breast cancer, in combination with Faslodex, has been approved by the US Food & Drug Administration. This follows the results from its CapItello-291 phase 3 trial published earlier this year, which showed reduced risk of disease progression or death by 50% compared to Faslodex alone. AstraZeneca Executive Vice President, Oncology Business Unit Dave Fredrickson commented: "The rapid US approval of Truqap reinforces the important role of the PI3K/AKT pathway in HR-positive breast cancer and the critical need to test patients at the time of diagnosis, as up to fifty per cent have tumours with these alterations. As a first-in-class medicine, this approval provides a critical new option for patients in the US with this specific type of disease and we look forward to bringing Truqap to the many breast cancer patients who can benefit across the globe."

----------

COMPANIES - FTSE 250

----------

PureTech Health said its founded entity Karuna Therapeutics has announced positive results from its phase 1b ambulatory blood pressure monitoring trial of KarXT in treating schizophrenia. The biotechnology firm said results demonstrate that KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia. This is alongside meeting its primary endpoint of demonstrating a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of negative 0.59 millimetres of mercury. It said KarXT was "generally well tolerated", with a side effect profile consistent with prior trials in the Emergent programme evaluating KarXT in schizophrenia.

----------

OTHER COMPANIES

----------

FRP Advisory said its performance was strong during the half-year that ended October 31. The corporate finance, restructuring and debt adviser said it expects first half revenue of GBP58.7 million, up 19% from GBP49.4 million a year earlier, alongside underlying adjusted earnings before interest, tax, depreciation and amortisation rising 34% to GBP15.5 million from GBP11.6 million. It noted the restructuring having seen an increase in activity levels during calendar 2023, including administrations approaching pre-pandemic levels. The company said: "Companies with significant borrowings who have rolled off lower interest rate arrangements are now subject to much higher debt service costs, with interest rates now considerably higher than the 2009-2021 period...Certain sectors such as construction, property, casual dining and food service, retail, administrative and support services are finding current trading conditions particularly challenging." Chief Executive Officer Geoff Rowley added: "We remain confident of making further progress, with leading positions in our core markets and a team and structure that leaves us well positioned to support corporates through the business cycle and respond to increased demand for our services."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
21 Oct 2020 20:31

IN BRIEF: PureTech's Akili Reports New Trial Data For EndeavorRx

IN BRIEF: PureTech's Akili Reports New Trial Data For EndeavorRx

Read more
5 Oct 2020 19:23

UK TRADING UPDATE SUMMARY: Staffline Pens New Deal, Extends Tesco Pact

UK TRADING UPDATE SUMMARY: Staffline Pens New Deal, Extends Tesco Pact

Read more
1 Oct 2020 21:23

IN BRIEF: PureTech Health Appoints Biocon Chair Shaw To Board

IN BRIEF: PureTech Health Appoints Biocon Chair Shaw To Board

Read more
23 Sep 2020 19:09

UK TRADING UPDATE SUMMARY: Joules In Lockdown Hit But Online Surges

UK TRADING UPDATE SUMMARY: Joules In Lockdown Hit But Online Surges

Read more
4 Sep 2020 15:42

IN BRIEF: PureTech's Gelesis Presents Plenity Efficacy & Safety Data

IN BRIEF: PureTech's Gelesis Presents Plenity Efficacy & Safety Data

Read more
27 Aug 2020 15:26

Puretech Health Interim Earnings Surge On Contracts, Product Approvals

Puretech Health Interim Earnings Surge On Contracts, Product Approvals

Read more
26 Aug 2020 14:15

IN BRIEF: PureTech Sells 1.3 Million Karuna Shares For USD100 Million

IN BRIEF: PureTech Sells 1.3 Million Karuna Shares For USD100 Million

Read more
25 Aug 2020 15:21

PureTech Health's Affiliate Sonde Buys NeuroLex Laboratories

PureTech Health's Affiliate Sonde Buys NeuroLex Laboratories

Read more
20 Aug 2020 15:59

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
30 Jul 2020 18:00

UK EXECUTIVE CHANGE SUMMARY: 65-Year Stint At Heavitree Brewery Ends

UK EXECUTIVE CHANGE SUMMARY: 65-Year Stint At Heavitree Brewery Ends

Read more
29 Jul 2020 15:00

Liberum raises target price on 'underappreciated' PureTech Health

(Sharecast News) - Analysts at Liberum raised their target price on biotechnology company PureTech Health from 450.0p to 490.0p on Wednesday, stating the firm had made some "underappreciated" progress.

Read more
29 Jul 2020 13:29

Wednesday broker round-up

(Sharecast News) - Sanne: RBC Capital Markets reiterates sector performer with a target price of 600.0p.

Read more
12 Jul 2020 16:51

Sunday share tips: PureTech, Driver Group

(Sharecast News) - The Sunday Times's Sabah Meddings told readers of her 'Inside the City' column to 'buy' shares of PureTech, citing the the drug maker's ingenious 'portfolio' approach and ample pipeline of treatments in various phases of development.

Read more
8 Jul 2020 15:50

IN BRIEF: PureTech's Sonde Launches Virus Safe Voice Sample Health App

IN BRIEF: PureTech's Sonde Launches Virus Safe Voice Sample Health App

Read more
8 Jul 2020 15:13

Peel Hunt says Vor Biopharma cash call validates Puretech Health's model

(Sharecast News) - Analysts at Peel Hunt reiterated their 'Conviction Buy' recommendation for shares of PureTech Health following a $110.0m funding round for its founded entity Vor Biopharma, arguing that the transaction validated its business model.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.